Literature DB >> 20958323

Ex vivo- and in vivo-induced dead tumor cells as modulators of antitumor responses.

Eva-Maria Weiss1, Benjamin Frey, Franz Rödel, Martin Herrmann, Eberhard Schlücker, Reinhard E Voll, Rainer Fietkau, Udo S Gaipl.   

Abstract

Joint application of standard tumor therapies like radiotherapy and/or chemotherapy with immune therapy has long been considered not to fit. However, it has become accepted that immune responses may contribute to the elimination of cancer cells. We present how in vivo-induced tumor cell death by irradiation, chemotherapeutic agents, or hyperthermia can be rendered more immunogenic. High hydrostatic pressure is introduced as an innovative inactivation method for tumor cells used as vaccines. Annexin A5, being a natural occurring ligand for phosphatidylserine that is exposed by dying tumor cells, renders apoptotic tumor cells immunogenic and induces tumor regression. Combinations of irradiation with hyperthermia may also foster antitumor responses. For preparation of autologous tumor cell vaccines, high hydrostatic pressure is suitable to induce immunogenic cancer cell death. Future work will be aimed toward evaluating which combination and chronological sequence of radiotherapy, chemotherapy, hyperthermia, annexin A5, and/or autologous tumor cell vaccines will induce specific and long-lasting antitumor immunity.
© 2010 New York Academy of Sciences.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20958323     DOI: 10.1111/j.1749-6632.2010.05743.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  10 in total

1.  In vivo targeting of cell death using a synthetic fluorescent molecular probe.

Authors:  Bryan A Smith; Shuzhang Xiao; William Wolter; James Wheeler; Mark A Suckow; Bradley D Smith
Journal:  Apoptosis       Date:  2011-07       Impact factor: 4.677

Review 2.  Key mechanisms involved in ionizing radiation-induced systemic effects. A current review.

Authors:  Ifigeneia V Mavragani; Danae A Laskaratou; Benjamin Frey; Serge M Candéias; Udo S Gaipl; Katalin Lumniczky; Alexandros G Georgakilas
Journal:  Toxicol Res (Camb)       Date:  2015-08-11       Impact factor: 3.524

Review 3.  Consensus guidelines for the detection of immunogenic cell death.

Authors:  Oliver Kepp; Laura Senovilla; Ilio Vitale; Erika Vacchelli; Sandy Adjemian; Patrizia Agostinis; Lionel Apetoh; Fernando Aranda; Vincenzo Barnaba; Norma Bloy; Laura Bracci; Karine Breckpot; David Brough; Aitziber Buqué; Maria G Castro; Mara Cirone; Maria I Colombo; Isabelle Cremer; Sandra Demaria; Luciana Dini; Aristides G Eliopoulos; Alberto Faggioni; Silvia C Formenti; Jitka Fučíková; Lucia Gabriele; Udo S Gaipl; Jérôme Galon; Abhishek Garg; François Ghiringhelli; Nathalia A Giese; Zong Sheng Guo; Akseli Hemminki; Martin Herrmann; James W Hodge; Stefan Holdenrieder; Jamie Honeychurch; Hong-Min Hu; Xing Huang; Tim M Illidge; Koji Kono; Mladen Korbelik; Dmitri V Krysko; Sherene Loi; Pedro R Lowenstein; Enrico Lugli; Yuting Ma; Frank Madeo; Angelo A Manfredi; Isabelle Martins; Domenico Mavilio; Laurie Menger; Nicolò Merendino; Michael Michaud; Gregoire Mignot; Karen L Mossman; Gabriele Multhoff; Rudolf Oehler; Fabio Palombo; Theocharis Panaretakis; Jonathan Pol; Enrico Proietti; Jean-Ehrland Ricci; Chiara Riganti; Patrizia Rovere-Querini; Anna Rubartelli; Antonella Sistigu; Mark J Smyth; Juergen Sonnemann; Radek Spisek; John Stagg; Abdul Qader Sukkurwala; Eric Tartour; Andrew Thorburn; Stephen H Thorne; Peter Vandenabeele; Francesca Velotti; Samuel T Workenhe; Haining Yang; Wei-Xing Zong; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-12-13       Impact factor: 8.110

Review 4.  Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy.

Authors:  Irena Adkins; Jitka Fucikova; Abhishek D Garg; Patrizia Agostinis; Radek Špíšek
Journal:  Oncoimmunology       Date:  2015-01-07       Impact factor: 8.110

5.  Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy.

Authors:  Romana Mikyšková; Ivan Štěpánek; Marie Indrová; Jana Bieblová; Jana Šímová; Iva Truxová; Irena Moserová; Jitka Fučíková; Jiřina Bartůňková; Radek Špíšek; Milan Reiniš
Journal:  Int J Oncol       Date:  2015-12-29       Impact factor: 5.650

6.  Mechanisms for enhanced antitumor immune responses induced by irradiated hepatocellular carcinoma cells engineered to express hepatitis B virus X protein.

Authors:  Anliang Huang; Jinhu Ma; Liyan Huang; Fan Yang; Ping Cheng
Journal:  Oncol Lett       Date:  2018-04-04       Impact factor: 2.967

7.  Combination Treatment of Stereotactic Body Radiation Therapy and Immature Dendritic Cell Vaccination for Augmentation of Local and Systemic Effects.

Authors:  Chul Won Choi; Min Ho Jeong; You-Soo Park; Cheol-Hun Son; Hong-Rae Lee; Eun-Kyoung Koh
Journal:  Cancer Res Treat       Date:  2018-06-06       Impact factor: 4.679

8.  Selected anti-tumor vaccines merit a place in multimodal tumor therapies.

Authors:  Eva-Maria Weiss; Roland Wunderlich; Nina Ebel; Yvonne Rubner; Eberhard Schlücker; Roland Meyer-Pittroff; Oliver J Ott; Rainer Fietkau; Udo S Gaipl; Benjamin Frey
Journal:  Front Oncol       Date:  2012-10-09       Impact factor: 6.244

9.  99mTc-HYNIC-Annexin A5 in Oncology: Evaluating Efficacy of Anti-Cancer Therapies.

Authors:  Frédéric L W V J Schaper; Chris P Reutelingsperger
Journal:  Cancers (Basel)       Date:  2013-05-15       Impact factor: 6.639

10.  Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccines.

Authors:  Grégoire Wieërs; Nathalie Demotte; Danièle Godelaine; Pierre Van der Bruggen
Journal:  Cancers (Basel)       Date:  2011-07-18       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.